These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 23292766)
1. Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease. Kallaur AP; Oliveira SR; Colado Simão AN; Delicato de Almeida ER; Kaminami Morimoto H; Lopes J; de Carvalho Jennings Pereira WL; Marques Andrade R; Muliterno Pelegrino L; Donizete Borelli S; Kaimen-Maciel DR; Reiche EM Mol Med Rep; 2013 Mar; 7(3):1010-20. PubMed ID: 23292766 [TBL] [Abstract][Full Text] [Related]
2. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227 [TBL] [Abstract][Full Text] [Related]
3. The role of endogenous antiradical protective system in multiple sclerosis. Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726 [TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis. Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104 [TBL] [Abstract][Full Text] [Related]
5. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis. Trenova AG; Slavov GS; Manova MG; Kostadinova II Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430 [TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis. Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369 [TBL] [Abstract][Full Text] [Related]
7. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860 [TBL] [Abstract][Full Text] [Related]
8. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis. Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252 [TBL] [Abstract][Full Text] [Related]
9. Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study. Stępień A; Chalimoniuk M; Lubina-Dąbrowska N; Chrapusta SJ; Galbo H; Langfort J Neuroimmunomodulation; 2013; 20(4):213-22. PubMed ID: 23711618 [TBL] [Abstract][Full Text] [Related]
10. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273 [TBL] [Abstract][Full Text] [Related]
11. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels. Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963 [TBL] [Abstract][Full Text] [Related]
12. Female sex hormones and cytokine secretion in women with multiple sclerosis. Trenova AG; Slavov GS; Manova MG; Kostadinova II; Vasileva TV Neurol Res; 2013 Jan; 35(1):95-9. PubMed ID: 23317804 [TBL] [Abstract][Full Text] [Related]
13. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action. Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487 [TBL] [Abstract][Full Text] [Related]
14. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients. D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L Front Immunol; 2018; 9():1240. PubMed ID: 29915590 [TBL] [Abstract][Full Text] [Related]